searching for a cure

Houston biotech company launches animal testing on a drug that could treat COVID-19

A COVID-19 treatment is entering into the next phase of testing. Photo via Getty Images

A clinical stage pharmaceutical company based in Houston has entered into the next phase of testing out a drug that could be used to treat COVID-19.

Moleculin Biotech Inc. has tapped an independent lab to examine the antiviral activity of its WP1122 portfolio in a COVID-19 animal model. The drug was originally developed as a cancer-fighting glycolysis inhibitor and submitted for its COVID-19 treatment patent in April.

"With in vivo studies for the treatment of COVID-19 in such high demand, we are excited to begin an in vivo study involving our WP1122 portfolio," says Walter Klemp, chairman and CEO of Moleculin, in a press release. "Even though we may have initial observations earlier, having the final data readout in December will push the estimated window for filing an Investigational New Drug application into 2021.

"We are also planning to conduct other in vivo studies, intended to enable us to file a complete IND with the US Food and Drug Administration."

The in vivo study, which would use the lab's hamster model and SARS-CoV-2. Moleculin Biotech expects to have the data from the study in December.

"We are excited about the additional in vitro testing as this will involve more than one molecule from our WP1122 anitmetabolite portfolio against SARS-CoV-2 and other viruses," says Klemp.

Moleculin Biotech was founded by Klemp in 2007 and went public in 2016. The company is based in the Memorial Park area of Houston.

Trending News

Building Houston

 
 

Houston-based Hewlett Packard Enterprise announced its plans to acquire a Silicon Valley startup. Photo courtesy og HPE

Hewlett Packard Enterprise has announced its plans to acquire a San Jose, California-based startup.

HPE, which relocated its headquarters to Houston from the Bay Area a couple years ago, has agreed to acquire OpsRamp, a software-as-a-service company with an IT operations management, or ITOM, platform that can monitor, automate, and manage IT infrastructure, cloud resources, and more.

According to a news release from HPE, the OpsRamp platform will be merged with the HPE GreenLake edge-to-cloud platform, which supports more than 65,000 customers, powers over two million connected devices, and manages more than one exabyte of data with customers worldwide.

The new integrated system "will reduce the operational complexity of multi-vendor and multi-cloud IT environments that are in the public cloud, colocations, and on-premises," per the statement.

“Customers today are managing several different cloud environments, with different IT operational models and tools, which dramatically increases the cost and complexity of digital operations management,” says HPE's CTO Fidelma Russo in the release. “The combination of OpsRamp and HPE will remove these barriers by providing customers with an integrated edge-to-cloud platform that can more effectively manage and transform multi-vendor and multi-cloud IT estates.

"This acquisition advances HPE hybrid cloud leadership and expands the reach of the HPE GreenLake platform into IT Operations Management,” she continues.

HPE's corporate venture arm, Pathfinder, invested in OpsRamp in 2020. The company raised $57.5 million prior to the acquisition. Other investors included Morgan Stanley Expansion Capital and Sapphire Ventures, per TechCrunch.

“The integration of OpsRamp’s hybrid digital operations management solution with the HPE GreenLake platform will provide an unmatched offering for organizations seeking to innovate and thrive in a complex, multi-cloud world. Partners and the channel will also play a pivotal role to advance their as-a-service offerings, as enterprises look for a unified approach to better manage their operations from the edge to the cloud,” says Varma Kunaparaju, CEO of OpsRamp, in the release.

“We look forward to leveraging the scale and reach of HPE’s global go-to-market engine to deliver our unique offering and are excited for this journey ahead as part of HPE.”

Trending News